Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Price T Rowe Associates Inc. MD


Share on StockTwits

Price T Rowe Associates Inc. MD lessened its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 6.0% in the 4th quarter, Holdings Channel reports. The fund owned 80,902 shares of the company’s stock after selling 5,166 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Crinetics Pharmaceuticals were worth $1,142,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. BlackRock Inc. lifted its position in shares of Crinetics Pharmaceuticals by 17.5% in the 4th quarter. BlackRock Inc. now owns 2,113,195 shares of the company’s stock valued at $29,816,000 after acquiring an additional 314,497 shares in the last quarter. State Street Corp lifted its position in shares of Crinetics Pharmaceuticals by 5.9% in the 3rd quarter. State Street Corp now owns 443,775 shares of the company’s stock valued at $6,954,000 after acquiring an additional 24,800 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Crinetics Pharmaceuticals by 53.8% in the 4th quarter. Bank of New York Mellon Corp now owns 272,637 shares of the company’s stock valued at $3,848,000 after acquiring an additional 95,325 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Crinetics Pharmaceuticals by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 150,723 shares of the company’s stock valued at $2,127,000 after acquiring an additional 3,852 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Crinetics Pharmaceuticals by 9.9% in the 4th quarter. Rhumbline Advisers now owns 30,767 shares of the company’s stock valued at $434,000 after acquiring an additional 2,780 shares in the last quarter. Institutional investors and hedge funds own 92.15% of the company’s stock.

In other Crinetics Pharmaceuticals news, major shareholder Perceptive Advisors Llc purchased 304,136 shares of the company’s stock in a transaction dated Thursday, April 8th. The shares were bought at an average price of $16.44 per share, for a total transaction of $4,999,995.84. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.10% of the company’s stock.

Several research analysts have weighed in on CRNX shares. SVB Leerink reiterated a “buy” rating and issued a $33.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Thursday, April 1st. Zacks Investment Research lowered shares of Crinetics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Crinetics Pharmaceuticals presently has an average rating of “Hold” and an average target price of $30.75.

Crinetics Pharmaceuticals stock opened at $17.32 on Friday. The firm’s 50 day moving average price is $16.06 and its two-hundred day moving average price is $14.82. Crinetics Pharmaceuticals, Inc. has a twelve month low of $11.61 and a twelve month high of $23.70. The firm has a market cap of $572.06 million, a PE ratio of -7.22 and a beta of 1.24.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings results on Monday, March 29th. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.08). Research analysts expect that Crinetics Pharmaceuticals, Inc. will post -2.35 EPS for the current fiscal year.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors.

Featured Article: Investing in Dividend Stocks

Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX).

Institutional Ownership by Quarter for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.